Utah Medical Products, Inc. develops, manufactures and distributes medical devices for the healthcare industry. The company is headquartered in Midvale, Utah.
| Revenue (TTM) | $36.11M |
| Gross Profit (TTM) | $20.91M |
| EBITDA | $14.82M |
| Operating Margin | 36.90% |
| Return on Equity | 8.76% |
| Return on Assets | 6.10% |
| Revenue/Share (TTM) | $11.31 |
| Book Value | $37.80 |
| Price-to-Book | 1.80 |
| Price-to-Sales (TTM) | 6.26 |
| EV/Revenue | 3.675 |
| EV/EBITDA | 12.92 |
| Quarterly Earnings Growth (YoY) | -10.10% |
| Quarterly Revenue Growth (YoY) | -14.30% |
| Shares Outstanding | $3.18M |
| Float | $2.77M |
| % Insiders | 7.18% |
| % Institutions | 75.43% |
Volatility is currently expanding
UTMD's Q2 earnings per share decline 10.1% year over year, while quarterly revenues face pressure from lost customers and slower new business growth.
SALT LAKE CITY, UT / ACCESS Newswire / July 23, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) reports second calendar quarter (2Q) and first half (1H) 2026 financial results with a continued decline in overall revenues in comparison to the same time periods in 2025. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.
SALT LAKE CITY, UT / ACCESS Newswire / May 5, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty-one cents ($.31) per share of common stock payable on July 3, 2026 to stockholders of record at the close of business on June 17, 2026. This is a 1.6% increase over the dividend declared in the same quarter of the prior year.
UTMD reports a year-over-year decline in Q1 earnings per share and sales, pressured by lost distributor business and higher costs, despite improved margins and a strong balance sheet.
SALT LAKE CITY, UT / ACCESS Newswire / April 23, 2026 / In the first calendar quarter (1Q) of 2026, Utah Medical Products, Inc. (Nasdaq:UTMD) attained financial results which were consistent with its previously announced projections for calendar year 2026. But because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole.
UTMD's niche leadership, global footprint, and strong cash generation position it to benefit from rising demand for high-quality maternal and neonatal healthcare solutions.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on UTMD and any ticker you trade — then tracks every position and per-strategy win rate.
